Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cresco Labs (CRLBF) EBITDA (2020 - 2025)

Historic EBITDA for Cresco Labs (CRLBF) over the last 6 years, with Q3 2025 value amounting to -$22.2 million.

  • Cresco Labs' EBITDA fell 19492.56% to -$22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.0 million, marking a year-over-year decrease of 9056.82%. This contributed to the annual value of -$75.5 million for FY2024, which is 5795.39% up from last year.
  • Latest data reveals that Cresco Labs reported EBITDA of -$22.2 million as of Q3 2025, which was down 19492.56% from -$13.3 million recorded in Q2 2025.
  • Over the past 5 years, Cresco Labs' EBITDA peaked at $27.1 million during Q4 2023, and registered a low of -$264.0 million during Q3 2021.
  • Moreover, its 5-year median value for EBITDA was -$7.5 million (2024), whereas its average is -$27.1 million.
  • The largest annual percentage gain for Cresco Labs' EBITDA in the last 5 years was 462857.14% (2021), contrasted with its biggest fall of 115882.49% (2021).
  • Cresco Labs' EBITDA (Quarter) stood at $15.6 million in 2021, then crashed by 1022.28% to -$143.5 million in 2022, then skyrocketed by 118.89% to $27.1 million in 2023, then plummeted by 152.81% to -$14.3 million in 2024, then tumbled by 55.13% to -$22.2 million in 2025.
  • Its EBITDA was -$22.2 million in Q3 2025, compared to -$13.3 million in Q2 2025 and -$15.2 million in Q1 2025.